The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a meta-analysis study

2012 ◽  
Vol 132 (12) ◽  
pp. 2808-2819 ◽  
Author(s):  
Francesca Lantieri ◽  
Francesco Caroli ◽  
Isabella Ceccherini ◽  
Paola Griseri
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Meta Analysis ◽  
Medullary Thyroid ◽  
Analysis Study

scholarly journals Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis

2014 ◽  
Vol 82 (2) ◽  
pp. 280-285 ◽  
Author(s):  
Pierpaolo Trimboli ◽  
Giorgio Treglia ◽  
Leo Guidobaldi ◽  
Francesco Romanelli ◽  
Giuseppe Nigri ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Detection Rate ◽  
Meta Analysis ◽  
Medullary Thyroid

scholarly journals Calcitonin-secreting neuroendocrine neoplasms of the lung: a systematic review and narrative synthesis

2021 ◽  
Vol 10 (4) ◽  
pp. 447-461
Author(s):  
David C Llewellyn ◽  
Rajaventhan Srirajaskanthan ◽  
Royce P Vincent ◽  
Catherine Guy ◽  
Eftychia E Drakou ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Meta Analysis ◽  
A Priori ◽  
Neuroendocrine Neoplasm ◽  
Neuroendocrine Neoplasms ◽  
Cochrane Central Register ◽  
Medullary Thyroid ◽  
Stimulation Tests

Calcitonin-secreting neuroendocrine neoplasms of the lung are rare, with few cases reported in the literature. Differentiating between medullary thyroid carcinoma and an ectopic source of calcitonin secretion can represent a complex diagnostic conundrum for managing physicians, with cases of unnecessary thyroidectomy reported in the literature. This manuscript reports a case of ectopic hypercalcitonaemia from a metastatic neuroendocrine neoplasm of the lung with concurrent thyroid pathology and summarises the results of a systematic review of the literature. Medical Literature Analysis and Retrieval System Online, Excerpta Medica, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and SCOPUS databases were systematically and critically appraised for all peer reviewed manuscripts that suitably fulfilled the inclusion criteria established a priori. The protocol for this systematic review was developed according to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols, and followed methods outlined in The Cochrane Handbook for Systematic Reviews of Interventions. This systematic review is registered with PROSPERO. It is vital to consider diagnoses other than medullary thyroid carcinoma when presented with a patient with raised calcitonin, as it is not pathognomonic of medullary thyroid carcinoma. Lung neuroendocrine neoplasms can appear similar to medullary thyroid carcinoma histologically, they can secrete calcitonin and metastasize to the thyroid. Patients with medullary thyroid carcinoma may show stimulated calcitonin values over two or more times above the basal values, whereas calcitonin-secreting neuroendocrine neoplasms may or may not show response to stimulation tests. The present review summarises existing evidence from cases of ectopic hypercalcitonaemia to lung neuroendocrine neoplasms.

scholarly journals Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis

2010 ◽  
Vol 72 (4) ◽  
pp. 534-542 ◽  
Author(s):  
Johannes A. A. Meijer ◽  
Saskia le Cessie ◽  
Wilbert B. van den Hout ◽  
Job Kievit ◽  
Johannes W. Schoones ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Thyroid Carcinoma ◽  
Carcinoembryonic Antigen ◽  
Medullary Thyroid Carcinoma ◽  
Meta Analysis ◽  
Medullary Thyroid ◽  
Doubling Times

scholarly journals Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis

2018 ◽  
Vol 25 (6) ◽  
pp. 633-641 ◽  
Author(s):  
Huy Gia Vuong ◽  
Toru Odate ◽  
Hanh T T Ngo ◽  
Thong Quang Pham ◽  
Thao T K Tran ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Random Effect ◽  
Random Effect Model ◽  
Advanced Tumor Stage ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid ◽  
Advanced Tumor

There are ongoing debates with respect to the prognostic roles of molecular biomarkers in sporadic medullary thyroid carcinoma (MTC). In this study, we aimed at investigating the prognostic value of RET and RAS mutations – the two most common mutations in sporadic MTCs. A search was conducted in four electronic databases. Relevant data were extracted and pooled into odds ratios (OR), mean differences (MD) and corresponding 95% confidence intervals (CI) using the random-effect model. We used Egger’s regression test and visual of funnel plots to assess the publication bias. From 2581 studies, we included 23 studies with 964 MTCs for meta-analysis. Overall, the presence of RET mutation was associated with an elevated risk for lymph node metastasis (OR = 3.61; 95% CI = 2.33–5.60), distant metastasis (OR = 2.85; 95% CI = 1.64–4.94), advanced tumor stage (OR = 3.25; 95% CI = 2.02–5.25), tumor recurrence (OR = 3.01; 95% CI = 1.65–5.48) and patient mortality (OR = 2.43; 95% CI = 1.06–5.57). RAS mutation had no significant prognostic value in predicting tumor aggressiveness. To summarize, our results affirmed that RET mutation is a reliable molecular biomarker to identify a group of highly aggressive sporadic MTCs. It can help clinicians better assess patient prognosis and select appropriate treatment decisions.

Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma. A meta-analysis

2021 ◽  
Author(s):  
Luca Giovanella ◽  
Maria Luisa Garo ◽  
Luca Ceriani ◽  
Gaetano Paone ◽  
Alfredo Campenni ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Data Extraction ◽  
Meta Analysis ◽  
Standard Of Care ◽  
Likelihood Ratios ◽  
Predictive Values ◽  
Medullary Thyroid ◽  
Time Restrictions ◽  
Sensitivity Specificity

Abstract Objective This study aimed to determine the procalcitonin (ProCT) diagnostic accuracy in prediction and treatment monitoring of medullary thyroid carcinoma (MTC). Data Sources Electronic databases were searched for observational studies published until May 2021 without language or time restrictions. Study Selection Studies comparing ProCT and calcitonin accuracy were included. After removing duplicates and exclusion of not-eligible articles, relevant articles were screened independently by two reviewers. Eleven studies (4.5% of the identified studies) met the selection criteria. Data Extraction Two reviewers independently extracted data and assessed data quality and validity through QUADAS-2. Data Synthesis A meta-analysis was performed on sufficiently clinically and statistically homogeneous eleven studies (n = 5817 patients, 335 MTC patients). HSROC and bivariate methods were applied. Serum ProCT was found to be a highly accurate test for MTC diagnosis and monitoring. The pooled sensitivity, specificity, positive and negative likelihood ratios, AUC, and positive and negative predictive values for ProCT were 0.90 (95%CI: 0.71-0.97), 1.00 (95%CI: 0.85-1.00), 288 (95%CI: 5.6-14929.3), 0.10 (95%CI: 0.03-0.33), 0.97 (95%CI: 0.95-0.98), 99% and 2%. Conclusions The high accuracy, compounded with favorable analytical characteristics, give ProCT great potential to replace calcitonin as a new standard of care in the management of MTC.

Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta‐analysis

Head & Neck ◽  
2019 ◽  
Author(s):  
Huy Gia Vuong ◽  
An Thi Nhat Ho ◽  
Thao T. K. Tran ◽  
Jaume Capdevila ◽  
Mustafa Benekli ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Meta Analysis ◽  
Medullary Thyroid
Sign in / Sign up

Export Citation Format

Share Document